Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.49 |
| ▸ | USP14 | P54578 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 6/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628878 | 0.87 | TLR8 (0.41) | TLR8TLR9TLR7RETCHEK1 | |
| SCHEMBL23760696 | 0.86 | TLR8 (0.49) | TLR8TLR9TLR7RET | |
| SCHEMBL23760675 | 0.82 | TLR8 (0.45) | TLR8TLR9TLR7NOS3NOS1 | |
| SCHEMBL23760664 | 0.81 | TLR8 (0.40) | TLR8TLR9TLR7SIGMAR1 | |
| SCHEMBL23760703 | 0.81 | TLR9 (0.43) | TLR8TLR9TLR7 | |
| SCHEMBL23628802 | 0.80 | TLR8 (0.40) | TLR8TLR9TLR7 | |
| SCHEMBL23628806 | 0.80 | TLR9 (0.45) | TLR8TLR9TLR7RETSYK | |
| SCHEMBL23760737 | 0.79 | TLR8 (0.42) | TLR8TLR9TLR7 | |
| SCHEMBL23760674 | 0.78 | TLR8 (0.47) | TLR8TLR9TLR7RET | |
| SCHEMBL23760702 | 0.78 | TLR8 (0.43) | TLR8TLR9TLR7NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, PADI1 | TLR8 1800/4885TLR9 308/4885TLR7 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.